BIEL × Viant × VLMS × Strategic Marketing Partner
Strategic Equity Meets Scalable Healthcare Branding
Just as Viant scales production and VLMS drives distribution, a marketing firm can take an open-market equity stake in BIEL to become a compounding stakeholder—earning returns from rising PPS while also fueling the brand’s virality, consumer adoption, and shelf-space expansion.
Rather than holding volatile crypto or earning cash fees, this partner turns campaign performance into equity value.
Each Partner’s Strategic Role
Viant Medical Produces FDA-cleared wearables at scale—ActiPatch®, RecoveryRx®, RecoveryRx Vet®
VLMS Healthcare Activates distribution across pharmacy, retail, and reimbursement pathways
Marketing Company Drives influencer campaigns, retail activation, and global brand visibility
BIEL The product innovator and central equity platform powering this alliance
Shared Thesis: Equity Accumulation Over Speculative Spend
Just as companies added Bitcoin for long-term upside, these partners pursue BIEL stock at sub-penny PPS ($0.0001)—with real-world catalysts and recoverable value.
Milestone-Based PPS Growth
$400K quarterly revenue → PPS to $0.01
$10M profit → PPS to $0.04
Full U.S. insurance reimbursement → PPS to $0.25–$0.40
Veterinary + Global rollouts → Compounded equity upside
Secure, Regulated Holdings
Shares via brokerage, not wallet passwords
Institutional-grade recoverability and oversight
Tax-Free Early Profits
$40M in BIEL’s tax-loss carryforwards = shielded capital gains
Unified Flywheel for PPS Acceleration
Viant builds → Product supply scales
VLMS bills → Distribution & revenue unlock
Marketing firm amplifies → Brand awareness and consumer adoption explode
BIEL executes milestones → PPS rises, equity compounding begins
All partners gain → Stake values multiply without dilution
Strategic Equity Meets Scalable Healthcare Branding
Just as Viant scales production and VLMS drives distribution, a marketing firm can take an open-market equity stake in BIEL to become a compounding stakeholder—earning returns from rising PPS while also fueling the brand’s virality, consumer adoption, and shelf-space expansion.
Rather than holding volatile crypto or earning cash fees, this partner turns campaign performance into equity value.
Each Partner’s Strategic Role
Viant Medical Produces FDA-cleared wearables at scale—ActiPatch®, RecoveryRx®, RecoveryRx Vet®
VLMS Healthcare Activates distribution across pharmacy, retail, and reimbursement pathways
Marketing Company Drives influencer campaigns, retail activation, and global brand visibility
BIEL The product innovator and central equity platform powering this alliance
Shared Thesis: Equity Accumulation Over Speculative Spend
Just as companies added Bitcoin for long-term upside, these partners pursue BIEL stock at sub-penny PPS ($0.0001)—with real-world catalysts and recoverable value.
Milestone-Based PPS Growth
$400K quarterly revenue → PPS to $0.01
$10M profit → PPS to $0.04
Full U.S. insurance reimbursement → PPS to $0.25–$0.40
Veterinary + Global rollouts → Compounded equity upside
Secure, Regulated Holdings
Shares via brokerage, not wallet passwords
Institutional-grade recoverability and oversight
Tax-Free Early Profits
$40M in BIEL’s tax-loss carryforwards = shielded capital gains
Unified Flywheel for PPS Acceleration
Viant builds → Product supply scales
VLMS bills → Distribution & revenue unlock
Marketing firm amplifies → Brand awareness and consumer adoption explode
BIEL executes milestones → PPS rises, equity compounding begins
All partners gain → Stake values multiply without dilution
